+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Scleroderma - Pipeline Insight, 2021

  • ID: 5305165
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 150 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • ChemomAb
  • Corbus Pharmaceuticals
  • CSL Behring
  • Fibrocell Science
  • Formation Biologics
  • Gesynta Pharma
  • MORE

This “Scleroderma - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Scleroderma Understanding

Scleroderma: Overview

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Scleroderma affects women more often than men and most commonly occurs between the ages of 30 and 50. While there is no cure for scleroderma, a variety of treatments can ease symptoms and improve quality of life. There are many different types of scleroderma. In some people, scleroderma affects only the skin. But in many people, scleroderma also harms structures beyond the skin, such as blood vessels, internal organs and the digestive tract (systemic scleroderma). Scleroderma results from an overproduction and accumulation of collagen in body tissues. There are 2 main types of scleroderma: localised scleroderma - just affects the skin and systemic sclerosis - may affect blood circulation and internal organs as well as the skin.

"Scleroderma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scleroderma pipeline landscape is provided which includes the disease overview and Scleroderma treatment guidelines. The assessment part of the report embraces, in depth Scleroderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scleroderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma.

Scleroderma Emerging Drugs Chapters

This segment of the Scleroderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Scleroderma Emerging Drugs

Lenabasum: Corbus Pharmaceuticals

Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. It is currently in Phase III for Systemic scleroderma and is being developed by Corbus Pharmaceuticals.

EHP 101: Emerald Health Pharmaceuticals

EHP-101 is an oral formulation of a new chemical entity derived from synthetic cannabidiol, also known as CBD, one of the most abundant molecules found in the cannabis plant. The fully synthetic novel molecule formulated in EHP-101 has been rationally designed to enhance the therapeutic benefits of CBD by being a dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid type 2 receptor (CB2) agonist that also activates the hypoxia inducible factor (HIF) pathway. It is currently in Phase II scleroderma and is being developed by Emerald Health Pharmaceuticals.

Scleroderma: Therapeutic Assessment

This segment of the report provides insights about the different Scleroderma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Scleroderma

There are approx. 30+ key companies which are developing the therapies for Scleroderma. The companies which have their Scleroderma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

Phases

This report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scleroderma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scleroderma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scleroderma drugs.

Scleroderma Report Insights

  • Scleroderma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Scleroderma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Scleroderma drugs?
  • How many Scleroderma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scleroderma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scleroderma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Scleroderma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Corbus Pharmaceuticals
  • Emerald Health Pharmaceuticals
  • Gesynta Pharma
  • Formation Biologics
  • Fibrocell Science
  • CSL Behring
  • ChemomAb
  • Luminary Therapeutics

Key Products

  • Lenabasum
  • EHP 101
  • GS-248
  • AVID200
  • FCX-013
  • IgPro20
  • CM-101
  • LMY 920

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ChemomAb
  • Corbus Pharmaceuticals
  • CSL Behring
  • Fibrocell Science
  • Formation Biologics
  • Gesynta Pharma
  • MORE
Introduction

Executive Summary

Scleroderma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Scleroderma - Analytical Perspective

In-depth Commercial Assessment
  • Scleroderma companies' collaborations, Licensing, Acquisition -Deal Value Trends
Scleroderma Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Lenabasum: Corbus Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
EHP 101: Emerald Health Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
CM-101: ChemomAb
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
LMY 920: Luminary Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Scleroderma Key Companies

Scleroderma Key Products

Scleroderma- Unmet Needs

Scleroderma- Market Drivers and Barriers

Scleroderma- Future Perspectives and Conclusion

Scleroderma Analyst Views

Scleroderma Key Companies

Appendix

List of Tables
Table 1 Total Products for Scleroderma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Scleroderma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Corbus Pharmaceuticals
  • Emerald Health Pharmaceuticals
  • Gesynta Pharma
  • Formation Biologics
  • Fibrocell Science
  • CSL Behring
  • ChemomAb
  • Luminary Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll